The Statin Market will register a CAGR of over 2% by 2023

Tuesday, December 4, 2018 Heart Disease News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 3, 2018 /PRNewswire/ -- 129 pages, October 2018About this marketThe increasing

statin use will help the market grow at a steady rate. In the US and the UK, people aged 40 and above are recommended to monitor their cholesterol level. Statins are considered an evidence-based treatment for high risk patients with elevated cardiovascular
disorder. Technavio's analysts have predicted that the statin market will register a CAGR of over 2% by 2023.Read the full report: https://www.reportlinker.com/p03095480 Market OverviewRising prevalence of hypercholesterolemiaThe rising prevalence of hypercholesterolemia is fueling the demand for generic cholesterol medications. Cardiovascular disease is one of the primary causes of mortality in Western countries.Fierce generic competitionPatient expiration is a major challenge for companies developing branded drugs as it provides an opportunity for the development of generic drugs.For the detailed list of factors that will drive and challenge the growth of the statin market during the 2019-2023, view our report.Competitive LandscapeThe market appears to be fragmented and with the presence of several companies including AstraZeneca and Merck the competitive environment is quite intense. Factors such as the increasing statin use and the rising prevalence of hypercholesterolemia, will provide considerable growth opportunities to statin manufactures. AstraZeneca, Merck, Pfizer, and Novartis are some of the major companies covered in this report.'With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies. Many established statin manufacturers are vying for their share of the global statin market, and the new players must differentiate themselves to gain vital traction over their competitors.'Read the full report: https://www.reportlinker.com/p03095480 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-statin-market-will-register-a-cagr-of-over-2-by-2023-300759055.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store